[1] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
[2] |
CHENG Kuan.
New progress in research and application of fenneridone
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.
|
[3] |
FAN Jianfeng,FANG Yi,ZHENG Chunhua.
Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
|
[4] |
WEI Zihan,LI Dongbo,YUAN Zheng,LU Ying, YANG Guojie.
Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
|
[5] |
JIN Yuelong, WANG Linhong, ZHU Lijun, LIANG Wei, DUAN Ying, YANG Song, CHEN Yanchun, ZHAO Xianghai, SHEN Chong, YAO Yingshui.
Association study of NOS3 genetic polymorphism and the efficacy of anti-hypertensive drug treatment on patient with essential hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 538-544.
|
[6] |
GUO Dao-xia, CHEN Yan-chun, WANG Lin-hong, LU Wei, SHEN Chong, YANG Song, ZHAO Xiang-hai, JIN Yue-long, YAO Ying-shui.
Association of HMGB1 gene polymorphism and drug treatment in patient with essential hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 766-771.
|
[7] |
TANG Hong-mei, TU Xing, CHAI Yu-na.
Experimental study on the rationality of amiloride off-label use in treating primary aldosteronism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1116-1120.
|
[8] |
HUANG Yao-hua, TANG Xin-ran, WANG Yang, ZHAO Yan-yan, LI Wei.
Application of SAS procedures in evaluation of trough/peak ratio in ambulatory blood pressure monitoring
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1246-1250.
|
[9] |
YIN Fang, LI Yun-fei, HUANG Ji-han, LI Lu-jin, ZHENG Qing-shan.
A example introduce: clinical design and quantitative evaluation of ambulatory blood pressure monitoring for once daily antihypertensive drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 666-671.
|
[10] |
XU Cheng-hua, YANG Yu-wen, CAO Heng.
Effectes of β1-adrenergic receptor and CYP2D6 gene polymorphism on metoprolol antihypertension therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1414-1418.
|
[11] |
PENG Cui-ying, ZHOU Cui-lan, HE Qing-zhi.
Association of TNF-α gene -308G/A polymorphism with essential hypertension in Han racial origin in Hunan
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 57-60.
|
[12] |
LIU Hua-qiang,YAN Mei-xing,WANG Shao-hua,SUN Xiao-lei.
Effects of bisoprolol with different drug administration time on the renin-angiotension-aldosterone system of non-dippers hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 101-104.
|
[13] |
LI Ling, TAN Zhi-rong, CHEN Yao, ZHOU Gan, GUO Dong, YAN Jin, YANG Guo-ping, OUYANG Dong-sheng.
A rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 809-813.
|
[14] |
WU Xiao-dong, ZHANG Dao-you, CUI Ming-chun, YANG Li-cai, YANG Yan-lang, ZHU Xin-jian.
Influence of valsartan and fluvastatin on hepatocyte growth factor in adriamycin-induced nephrotic rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 305-309.
|
[15] |
WANG Xin, YANG Yu-wen, WANG An-cai, KONG Xiang-quan.
Effects of valsartan on BKCa of hypoxic pulmonary hypertensive rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1032-1035.
|